Figure 8. A schematic model for a proposed action mechanism of the mAb 67-2.

The 67-2 is accessible to and eliminate unengaged basolateral OCLN through inhibiting oligomerization of OCLN irrespective of the presence or absence of HCV, thereby preventing the entry.